Genomics
📋 KEY NURSING CONSIDERATIONS
Consider the need for assessment, information provision, support or management on the following topics:
📌 PRACTICE RECOMMENDATIONS
Assess and support understanding of genomics relevant to a person’s diagnosis or genetic risk of a gynaecological cancer, and provide tailored clinical and psychosocial supportive care.
WHEN?
At key points such as pre-diagnosis, diagnosis, during treatment and during follow-up.
HOW?
- Assess and discuss understanding of genetic risk, genomic testing and targeted therapy.
- Provide tailored information, including written materials.
- Facilitate access to genetic counselling and support to discuss risk and implications for family.
Offer and facilitate access to a specialist cancer nurse for all people with a gynaecological cancer.
WHEN?
At key points such as pre-diagnosis, diagnosis, during treatment and during follow-up. Continue to offer, even if the patient has previously declined specialist nurse referral.
HOW?
- Offer and facilitate referral to a specialist cancer nurse with expertise in gynaecological cancers.
- The nurse may be available through the treating centre, or through specialist cancer support services via the ACNNP, such as Ovarian Cancer Australia or the McGrath Foundation.
Screen and/or assess people with gynaecological cancers for determinants of health that may influence their cancer experience and the delivery of culturally safe and equitable care.
WHEN?
An initial comprehensive screen or assessment as soon as possible from first contact. Review when there are changes in circumstance, health condition or transitions of care.
HOW?
- Use a validated screening tool to assess needs, such as the Nursing Equity Assessment Tool (NEAT) or the GYN Distress Thermometer and Problem List.
EVIDENCE
- Chung H, Crone E, Gough K, Hyatt A, Milne D, Krishnasamy M. Equity in cancer care: clinical utility analysis of the Nursing Equity Assessment Tool (NEAT). Support Care Cancer. 2024;33(1):60.
- Harbeck E, Chambers S, Porter-Steele J, et al. Screening for distress in women with gynaecological cancer: adaptation of the distress thermometer. Eur J Cancer Care. 2021;30(6):e13486.
Facilitate supportive care needs screening using patient-reported outcome measures (PROMs) to prioritise care that meets self-determined needs.
WHEN?
At a minimum, at key points such as pre-diagnosis, diagnosis, during treatment and during follow-up. Make contact as soon as possible after screening to manage any risk (e.g. high distress).
HOW?
- Facilitate patients to complete a validated supportive care needs screening tool (e.g. GYN Distress Thermometer and Problem List).
- Assess the results.
- Prioritise and manage care according to identified needs.
- Facilitate referrals as indicated.
EVIDENCE
- Cancer Council Victoria and Department of Health Victoria. Optimal care pathway for women with cervical cancer. 2020.
- Cancer Council Victoria and Department of Health Victoria. Optimal care pathway for women with ovarian cancer, 2nd ed. 2021.
- Cancer Council Victoria and Department of Health Victoria. Optimal care pathway for women with endometrial cancer. 2021.
- Button E, Thamm C, Crichton M, et al. Patient preferences for cancer nurses as care providers: a systematic review of discrete choice experiments. J Adv Nurs.
Recognise the central role of family, culture and community in the care of Aboriginal and Torres Strait Islander people with a gynaecological cancer, and incorporate these into assessment, treatment
WHEN?
As soon as a person has identified as Aboriginal and/or Torres Strait Islander.
HOW?
- Engage in cultural training and actively apply these learnings when caring for Aboriginal and/or Torres Strait Islander people.
- Seek permission to refer to an Aboriginal or cultural liaison officer, nurse navigator or other support role, if available.
EVIDENCE
- Cancer Australia. Optimal care pathway for Aboriginal and Torres Strait Islander people with cancer, 2nd ed. 2024.
- Pye K, Totton N, Stuart N, et al. Trial of Optimal Personalised Care After Treatment for Gynaecological cancer (TOPCAT-G). Pilot Feasibility Stud. 2016;2:67.
- NSW Cancer Institute. Helping Mob Live Healthy and Prevent Cancer: toolkit for the Aboriginal health workforce. n.d.
- Cancer Australia. Gynaecological cancers: a handbook for Aboriginal and Torres Strait Islander Health Workers and Health Practitioners. 2024.
Advocate within the multidisciplinary team on patients’ supportive care needs and goals of care, and advise on strategies to reduce impacts.
WHEN?
At all points of care, including during and after multidisciplinary team meetings.
HOW?
- All nurses: provide patient advocacy at all stages of care.
- At the MDT meeting, a specialist gynaecological cancer nurse should attend and represent the patient’s supportive care needs and goals of care, contributing insight into psychosocial, physical, cultural or practical considerations that may influence treatment planning.
- Ensure holistic needs are addressed, including referral to allied health, specialist nursing or community support services.
- Continue advocacy outside the meeting by supporting the patient’s understanding of MDT decisions and coordinating follow-up actions.
Support patients’ understanding of clinical trials and, where indicated, advocate for and coordinate referral to appropriate trials.
WHEN?
From diagnosis and at key points throughout treatment and beyond.
HOW?
- Discuss clinical trials and provide, or direct patients to, credible information sources.
- Assess supportive care needs relevant to trial participation.
- Provide emotional and psychosocial care, whether or not trials are available for the patient.
EVIDENCE
- Cancer Council Victoria and Department of Health Victoria. Optimal care pathway for women with cervical cancer. 2020.
- Cancer Council Victoria and Department of Health Victoria. Optimal care pathway for women with ovarian cancer, 2nd ed. 2021.
- Cancer Council Victoria and Department of Health Victoria. Optimal care pathway for women with endometrial cancer. 2021.
🔬 TUMOUR-SPECIFIC CONSIDERATIONS
UPDATE
Cervical cancer
- Neoadjuvant treatment typically not used
Gestational trophoblastic disease/neoplasia
- Neoadjuvant treatment typically not used
Ovarian cancers (including fallopian tube & primary peritoneal cancers)
- Consider referral for multidisciplinary prehabilitation, if service available
- Assess for chemotherapy-induced peripheral neuropathy (CIPN)
- Assess and monitor for ascites
- Assess and provide information and care on bowel management (i.e. diarrhoea, constipation, monitor for bowel obstruction)
- Assess for nausea and vomiting and potential risk for malnutrition
- Assess emotional wellbeing, e.g. fear of recurrence
- Assess need for a central venous access device (CVAD)
- Refer to Ovarian Cancer Australia Teal Support Program
Uterine cancers (including endometrial cancer)
- Chemotherapy may be recommended for palliative symptom control
- Educate on potential impacts of concurrent chemotherapy and radiotherapy
- Consider referral for multidisciplinary prehabilitation, if service available
Vaginal cancer
- Neoadjuvant treatment typically not used
Vulval cancer
- Neoadjuvant treatment typically not used
ABORIGINAL AND TORRES STRAIT ISLANDER PEOPLE
- Establish cultural preferences and sensitivity regarding Women’s Business
- Involve and support extended family, kin and community (mob)
- Allocate adequate time to build rapport at every interaction
- Ensure culturally safe communication and information (verbal and written), appropriate to health literacy level
- Recognise connection to Country and facilitate care on Country where possible
- Consider the use of cultural or bush medicine, or traditional healers that may be accessed by the person
- Seek permission to refer to an Aboriginal or cultural liaison officer, nurse navigator or other support role if available
- Ensure sensitivity and acknowledgement around Sorry Business